Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Risk-based patient selection for systematic biopsy in prostate cancer diagnosis has been adopted in daily clinical practice, either by clinical judgment and PSA testing, or using multivariate risk prediction tools.
|
31399825 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
We sought to determine the extent to which US Preventive Services Task Force (USPSTF) 2012 Grade D recommendations against prostate-specific antigen screening may have impacted recent prostate cancer disease incidence patterns in the United States across stage, National Comprehensive Cancer Network (NCCN) risk groups, and age groups.
|
31794057 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
A 72-year-old man with a history of T1cN0M0 prostate adenocarcinoma and rising prostate-specific antigen underwent a fluciclovine PET/CT scan that showed high uptake in several para-aortic nodes, suspicious for prostate cancer.
|
31652158 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
When men with a high Gleason grade prostate cancer receive radiation with external radiation and brachytherapy, the addition of radiation to the pelvis results in a longer duration of prostate-specific antigen control.
|
30992160 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Among patients with serum PSA level of 4 to 10 ng/mL (n = 121), the AMACR score was significantly higher in patients with PCa (<i>P</i> = 0.0002), while serum PSA showed no difference (<i>P</i> = 0.3023).
|
31793344 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
A high-risk Gleason score (8-10) was reported in 748 (67%) of patients in Epoch 1 and 1578 (63%) of patients in Epoch 2, and the median prostate-specific antigen level at initial prostate cancer diagnosis was higher in Epoch 1 patients than in Epoch 2 patients (68 vs. 35 ng/ml).
|
31704142 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition to its role in screening, PSA is also widely used in the management of patients with diagnosed prostate cancer such as in surveillance following diagnosis, monitoring response to therapy and in combination with both clinical and histological criteria in risk stratification for recurrence.
|
31714881 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Patients with organ-confined, node-negative prostate cancer who had biochemical failure (Prostate-specific antigen [PSA] less than 2.0) following prostatectomy were eligible for this phase I dose escalation trial.
|
31733323 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
The use of artificial urinary sphincter (AUS) for the treatment of stress urinary incontinence has become more prevalent, especially in the "prostate-specific antigen (PSA)-era", when more patients are treated for localized prostate cancer.
|
31736473 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We identified 6.509 patients with prostate cancer who had received hormonal therapy with a post-hormonal therapy PSA ≥2ng/mL, 363 of whom had non-metastatic, castrate-resistant prostate cancer.
|
31851457 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Rates of clinically significant prostate cancer in African Americans increased significantly following the 2012 US Preventative Services Task Force recommendation against prostate specific antigen screening: A Single Institution Retrospective Study.
|
31750596 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to design and evaluate the value of prostate-specific membrane antigen (PSA)-targeted manganese oxide-mesoporous silica nanoparticles (Mn-Msns) for the detection of prostate cancer.
|
31731188 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Individualized risk-adapted algorithms in prostate cancer (PCa) diagnosis using predictive prebiopsy variables in addition to prostate-specific antigen value may result in a considerable reduction of unnecessary systematic biopsies.
|
30868240 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
From April 2005-January 2016, 226 consecutive, prospectively evaluated prostate cancer patients underwent TTMB for either low-grade prostate cancer or persistently elevated prostate-specific antigen (PSA) and/or the presence of ASAP.
|
31020423 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Using prostate specific antigen (PSA) and prostate cancer antigen 3 (PCA3) in the diagnosis of prostate cancer, sensitivity and specificity still require improvement.
|
31430659 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
We identified the best cutoff values for prostate biopsy (0.25 for all prostate cancers and 0.20 for clinically significant prostate cancers) to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone.
|
31169140 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Using the Surveillance, Epidemiology, and End Results Prostate with AS/WW Database, all adult men diagnosed with localized low-risk prostate cancer (clinical T1-T2a, Gleason 6, and prostate-specific antigen <10 ng/mL) and managed with either AS/WW, radical prostatectomy, or radiotherapy were identified between 2010 and 2015.
|
31591454 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Implementation of organized prostate cancer screening has been challenging, in part because the PSA test is so amenable to opportunistic screening.
|
31314214 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Seminal citrate is superior to PSA for detecting clinically significant prostate cancer.
|
31808398 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to determine the prognostic significance of ERG and KPNA2 expression, and their association to early prostate-specific antigen (PSA) biochemical recurrence in advanced PC with lymph node metastases.
|
31809312 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
PSA alone does not appear to be sufficient to detect the persistence of residual prostate cancer after radiotherapy.
|
31628565 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
PSMA PET/CT should be considered to monitor PCa response to chemotherapy to detect early relapse, regardless of prostate-specific antigen levels, increasing the chances of finding low-volume oligoprogressive disease.
|
31693605 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Multivariable analysis revealed that ethnicity and PSA density (PSAD) are independent factors associated with overall prostate cancer detection rate.
|
30962017 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
Among subjects in a clinical trial with a prior negative biopsy, total PSA, free-PSA ratio and PSA density have comparable diagnostic characteristics for PCa screening in low and normal testosterone men.
|
31733275 |
2020 |
Malignant neoplasm of prostate
|
0.500 |
Biomarker
|
disease |
BEFREE |
The resulting area under the receiver operating characteristic curve (AUC) to predict csPCa was 0.76 for PI-RADS v2, 0.59 for age, and 0.67 for PSA density.
|
31690449 |
2020 |